Skip to main content
Research funding

Team of international scientific experts to advise on £50 million investment into type 1 diabetes research

The Type 1 Diabetes Grand Challenge – a partnership between the Steve Morgan Foundation, Diabetes UK and JDRF UK– has successfully appointed 17 leading international scientists to advise on its £50 million investment into type 1 diabetes research.
Breakthrough T1D profile picture
Kate Gerrard 22 November 2022

A grand appointment

The Type 1 Diabetes Grand Challenge – a partnership between the Steve Morgan Foundation, Diabetes UK and JDRF UK– has successfully appointed 17 leading international scientists to advise on its £50 million investment into type 1 diabetes research.

The scientists have joined one of three independent Scientific Advisory Panels each advising on a research area identified as having the greatest potential to transform treatments for type 1 diabetes:

  • The root causes of type 1 diabetes Panel, led by Professor Chantal Mathieu
  • The novel insulins Panel, led by Dr Tim Heise
  • The beta cell replacement Panel, led by Professor Matthias Hebrok

All three Panels are Chaired by Professor Simon Heller, a world-renowned diabetes specialist.

Further information on the Grand Challenge’s scope and ambition, and membership of the Scientific Advisory Panels, can be found on the Partnership’s new website.

The Grand Challenge website

The site also features latest Grand Challenge news, information about funding opportunities and funded projects. When research projects are underway it will also demonstrate and celebrate their impact.

Rachel Connor, Director of Research Partnerships at JDRF UK said: “We’re delighted to welcome so many globally renowned scientists, who are already giving us the benefit of their insight and expertise as we shape this Grand Challenge. They are ensuring the research we support through this game-changing partnership will best meet the needs of people living with type 1. The calibre of membership we’ve been able to attract to the new panels is testament to how thrilling the new research, supported by the partnership, will be.”

Dr Elizabeth Robertson, Director of Research at Diabetes UK said: “We are honoured to have so many of the world’s most distinguished diabetes researchers advising the Type 1 Diabetes Grand Challenge. Their expertise will help to ensure that every penny of the Steve Morgan Foundation’s £50 million gift is invested in bold, innovative research with the greatest potential to improve the lives of people with type 1 diabetes.

“We’re delighted to see the global research community united in their support of the Type 1 Diabetes Grand Challenge and look forward to seeing new, exciting research focusing on accelerating progress towards a cure for type 1 diabetes get underway next year.”

The new website can be found at type1diabetesgrandchallenge.org.uk

Related news

Read more
Older man speaking with female doctor whilst sat at a table
Research
13 March 2026

Tegoprubart: behind the headlines

You may have seen headlines or social media posts about a new drug called tegoprubart, with some suggesting it could help people with type 1 diabetes (T1D) stop taking insulin.

Read more
Breakthrough T1D
2 March 2026

How could ‘cyborg tissue’ help people with type 1 diabetes?

Researchers funded by Breakthrough T1D in America have used small, electrical implant systems in lab-grown, insulin-producing cells.

Read more
A man taking a continuous glucose monitor reading using his phone
Breakthrough T1D
27 February 2026

‘Vital’ NHS T1DE treatment pilot schemes set to end in April

A series of T1DE pilot schemes commissioned by NHS England are at risk of closure due to lack of funding.

Read more
B cell t cell black and white
Research
2 February 2026

What are B cells, and why do they matter in type 1 diabetes? New study highlights the importance of immune cell type

New research suggests that B cells play a major role in damaging protective immune cells called Tregs. Protecting Tregs could help protect insulin-producing cells in the early stages of T1D.